Search

Your search keyword '"O. Grimm"' showing total 285 results

Search Constraints

Start Over You searched for: Author "O. Grimm" Remove constraint Author: "O. Grimm" Database OpenAIRE Remove constraint Database: OpenAIRE
285 results on '"O. Grimm"'

Search Results

5. Integrating digital pathology and mathematical modelling to predict spatial biomarker dynamics in cancer immunotherapy

6. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

9. 1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

11. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

14. Förderung und Unterstützung der erfolgreichen Ausbildung zum Urologen durch die Deutsche Gesellschaft für Urologie

18. Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial

19. IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany

20. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

22. Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

23. Influence of prostate artery embolization on different qualities of micturition disorders

24. [Risk-adapted therapy for metastatic renal cell carcinoma]

25. HE-LHC: The High-Energy Large Hadron Collider Future Circular Collider Conceptual Design Report Volume 4

26. Risikoadaptierte Therapie des metastasierten Nierenzellkarzinoms

30. Erstlinientherapie des mRCC: ein Update

31. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination

33. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

34. Alpharadin-Therapie bei Patienten mit metastasiertem kastrationsrefraktärem Prostatakarzinom

35. Metastasiertes Prostatakarzinom

36. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

37. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

38. [Promotion and support of successful training as a urologist by the Deutsche Gesellschaft für Urologie]

39. [Follow-up of renal cell carcinoma in a nonmetastatic stage]

40. FCC Physics Opportunities

41. Aktueller Stand der Immunonkologie bei urologischen Tumoren

42. Metastasiertes kastrationsresistentes Prostatakarzinom

43. Diagnostik und Therapie retroperitonealer Abszesse

44. Therapiemonitoring und Nebenwirkungsmanagement bei PD-1/PD-L1-Immuncheckpoint-Inhibition

45. Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA

46. Erratum to : An update on renal cell carcinoma

47. T2 Mapping in Prostate Cancer

48. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]

49. [Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects]

50. Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214

Catalog

Books, media, physical & digital resources